Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2204–2210. doi: 10.1158/1535-7163.MCT-09-0160

Figure 5. NVP-BEZ235 attenuates VEGF secretion and inhibits factor VIII expression VEGF expression in-vivo.

Figure 5

(A) NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results. The amount of secreted VEGF was rendered in pg/ml/105 cells/24 h, as described previously (26). (B) Detection of factor VIII. Staining of factor VIII was used to measure the effect of NVP-BEZ235 on tumor angiogenesis. A drastic reduction in factor VIII–positive staining was noted in the NVP-BEZ235-treated (45mg/Kg) tumor section as compared with staining results in control cells.